Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B98
NCT04938817Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab + quavonlimab, lenvatinib, mk-4830, favezelimab + pembrolizumab and raludotatug deruxtecan in small cell lung cancer (SCLC) (5 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 60 months and 2 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
pembrolizumab + quavonlimablenvatinibmk-4830favezelimab + pembrolizumabraludotatug deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04938817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938817.